Login to Your Account



Earnings roundup


Monday, February 24, 2014
Exelixis Inc., of South San Francisco, reported net revenues of $4.3 million for the fourth quarter and $31.3 million for the full year, including net product revenues of $4.3 million and $15 million, respectively, for the fourth quarter and full year sales of Cometriq (cabozantinib), which was launched in January 2013 for medullary thyroid cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription